ACAD (ACADIA Pharmaceuticals) Interest Income: $33 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ACAD ACADIA Pharmaceuticals Inc ACAD
80 GF Score
Price $29.22
GF Value $24.89
Valuation Modestly Overvalued
! 10 Warning Signs
View Full Analysis

What is ACADIA Pharmaceuticals Interest Income?

ACADIA Pharmaceuticals ACAD +2.64% 80 Interest Income is $33 Mil as of Jun. 2026. GuruFocus rates ACAD with a GF Score™ of 80/100 and a GF Value™ of $24.89 (Modestly Overvalued). The stock has 10 warning signs investors should review.

Interest Income is the interest earned on cash temporarily held in savings accounts, certificates of deposits, or other investments. ACADIA Pharmaceuticals's interest income for the three months ended in Jun. 2026 was $8 Mil. Its interest income for the trailing twelve months (TTM) ended in Jun. 2026 was $33 Mil.

ACADIA Pharmaceuticals Interest Income Historical Data

* Premium members only.

The historical data trend for ACADIA Pharmaceuticals's Interest Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ACADIA Pharmaceuticals Interest Income Chart

ACADIA Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Interest Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.59 6.61 17.23 25.46 31.72

ACADIA Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Interest Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.24 8.25 8.33 8.06 7.99
ACAD
80GF Score
ACADIA Pharmaceuticals Inc ACAD
Interest Income is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ACADIA Pharmaceuticals Interest Income Calculation

Interest Income is the interest earned on cash temporarily held in savings accounts, certificates of deposits, or other investments.

Interest Income for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $33 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Income →
What does a Interest Income of $33 Mil mean?
ACADIA Pharmaceuticals (ACAD) has a Interest Income of $33 Mil as of Jun. 2026. Interest Income is the amount a company receives on savings accounts and certificates of deposits. View historical data on ACADIA Pharmaceuticals and its competitors.
Is ACADIA Pharmaceuticals' Interest Income too high?
ACADIA Pharmaceuticals' current Interest Income is $33 Mil. Overall, ACADIA Pharmaceuticals has a GF Score™ of 80/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does ACADIA Pharmaceuticals' Interest Income compare to LEGN and TNGX?
ACADIA Pharmaceuticals' Interest Income of $33 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Income for a Biotechnology company?
A good Interest Income depends on the Biotechnology industry context. However, Interest Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Income mean?
A high Interest Income can signal that a stock is expensive relative to its fundamentals. Interest Income is the amount a company receives on savings accounts and certificates of deposits. View historical data on ACADIA Pharmaceuticals and its competitors. ACADIA Pharmaceuticals's current Interest Income is $33 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ACADIA Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, ACADIA Pharmaceuticals (ACAD) is currently considered Modestly Overvalued. The stock's GF Value™ is $24.89, compared to a current price of $29.22 — trading 17.4% above its estimated fair value. The current Interest Income is $33 Mil. ACADIA Pharmaceuticals' overall GF Score™ is 80/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Income calculated?
Interest Income is calculated from a company's financial statements. For ACADIA Pharmaceuticals (ACAD), the current Interest Income is $33 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ACADIA Pharmaceuticals (ACAD) Overvalued in 2026?

Based on GuruFocus' analysis, ACADIA Pharmaceuticals stock appears to be overvalued. The current stock price of $29.22 is trading 17.4% above its estimated GF Value™ of $24.89. GuruFocus considers ACADIA Pharmaceuticals to be Modestly Overvalued.

Key valuation signals for ACAD:

  • Interest Income: $33 Mil
  • GF Value™: $24.89 vs. price of $29.22 (17.4% above fair value)
  • GF Score™: 80/100 with 10 warning signs

No single metric tells the full story. See the ACAD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ACADIA Pharmaceuticals Business Description

Other Exchanges ACAD:MexicoDR6:Germany
Address 12830 El Camino Real, Suite 400, San Diego, CA, USA, 92130
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-211, ACP-711, ACP-2591, etc.
80GF Score

Get the complete analysis for ACAD

Interest Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$29.22
Price
$24.89
GF Value